# TRANSFORM (NCT03575351)

> A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03575351
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Celgene
- Conditions: Lymphoma, Non-Hodgkin
- Interventions: Standard of Care; JCAR017
- Enrollment: 184
- Primary outcome: Event-free Survival (EFS) Per Independent Review Committee (IRC)

## Indexed commentary on TRANSFORM so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=transform-nct03575351